SELECT MEDICAL HOLDINGS CORP 8-K

What Happened
Select Medical Holdings Corporation (SEM) filed an 8‑K (June 22, 2026) saying it received three lawsuits (two in New York, one in Pennsylvania) and eleven demand letters challenging disclosures in the Definitive Proxy Statement for the proposed acquisition by a consortium led by Robert A. Ortenzio, Martin F. Jackson and Welsh, Carson, Anderson & Stowe. The special meeting to vote on the Merger is scheduled for June 26, 2026. To address the claims and avoid nuisance expense or delay, the company voluntarily supplemented the Definitive Proxy Statement with additional disclosures while denying the legal allegations.

Key Details

• Lawsuits: Two New York Supreme Court actions (Index Nos. 653282/2026 and 653290/2026) and one Pennsylvania suit (Cumberland County Case No. 2026‑06775‑0); plaintiffs seek injunctions, attorneys’ fees and (in NY) actual and punitive damages.
• Supplemental disclosures include an addendum that Parent intends to pay Mr. Ortenzio ≈ $2.9 million and Mr. Jackson ≈ $0.2 million after closing for their transaction roles (in addition to disclosed golden parachute payments).
• Financial valuation supplements: Goldman Sachs’ illustrative DCF implied present values per share of $15.04 to $25.33; an alternative implied present‑value analysis produced $14.04 to $25.72 per share; precedent‑transaction implied per‑share range noted as $9.99 to $29.87. Company net/total debt figures used in analyses: roughly $1.8 billion.
• Background additions: board discussions about separating the critical‑illness recovery hospital segment began in late June 2025; JPMorgan made a presentation on July 30, 2025; Goldman Sachs contacted nine potential bidders in the week of Jan 19, 2026.

Why It Matters

• Litigation could delay or block the proposed Merger (scheduled for a shareholder vote on June 26, 2026) or increase transaction costs if injunctions or additional disclosures are ordered.
• The supplemental disclosures (not admissions of wrongdoing) add material details investors may consider when voting—most notably the post‑closing fees to insiders (Ortenzio and Jackson) and expanded valuation inputs used by the Special Committee’s advisors.
• Investors should review the updated Definitive Proxy Statement and related SEC filings (available at sec.gov and Select Medical’s investor relations page) before voting; the company urges stockholders who have not yet submitted proxies to do so promptly.